ATE534377T1 - Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen - Google Patents

Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen

Info

Publication number
ATE534377T1
ATE534377T1 AT07794933T AT07794933T ATE534377T1 AT E534377 T1 ATE534377 T1 AT E534377T1 AT 07794933 T AT07794933 T AT 07794933T AT 07794933 T AT07794933 T AT 07794933T AT E534377 T1 ATE534377 T1 AT E534377T1
Authority
AT
Austria
Prior art keywords
compositions
methods
hematological diseases
treating hematological
compound
Prior art date
Application number
AT07794933T
Other languages
English (en)
Inventor
Lee Chong
William Lee
Adrian Ray
Hans Reiser
Daniel Tumas
William Watkins
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ATE534377T1 publication Critical patent/ATE534377T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Processing Of Solid Wastes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT07794933T 2006-05-16 2007-05-16 Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen ATE534377T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80098306P 2006-05-16 2006-05-16
US83180506P 2006-07-18 2006-07-18
PCT/US2007/011726 WO2007136650A2 (en) 2006-05-16 2007-05-16 Method and compositions for treating hematological malignancies

Publications (1)

Publication Number Publication Date
ATE534377T1 true ATE534377T1 (de) 2011-12-15

Family

ID=38578698

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07794933T ATE534377T1 (de) 2006-05-16 2007-05-16 Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen

Country Status (19)

Country Link
US (3) US20090258840A1 (de)
EP (1) EP2020996B1 (de)
JP (2) JP5544165B2 (de)
KR (1) KR101424832B1 (de)
CN (1) CN101442994B (de)
AT (1) ATE534377T1 (de)
AU (1) AU2007254309B2 (de)
BR (1) BRPI0711646C1 (de)
CA (1) CA2652048C (de)
CY (1) CY1112377T1 (de)
DK (1) DK2020996T3 (de)
EA (1) EA016995B1 (de)
ES (1) ES2377467T3 (de)
MX (1) MX2008014665A (de)
NZ (1) NZ572368A (de)
PL (1) PL2020996T3 (de)
PT (1) PT2020996E (de)
SI (1) SI2020996T1 (de)
WO (1) WO2007136650A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN109503584A (zh) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
PL2020996T3 (pl) * 2006-05-16 2012-04-30 Gilead Sciences Inc Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (de) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salzformen einer organischen verbindung
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (de) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, ein xanthinderivat als dpp-4-inhibitor zur verwendung bei der behandlung von sirs und/oder sepsis
EP3685839A1 (de) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
EP4233840A3 (de) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Kombinationen aus linagliptin und metformin
EP3808752A4 (de) * 2018-06-12 2022-03-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Phosphonamidesterverbindung, salz davon, verwandte kristallform davon, verfahren zu deren herstellung und deren verwendung
CN112168829B (zh) * 2020-09-24 2022-02-15 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
CN1291994C (zh) 2000-07-21 2006-12-27 吉里德科学公司 核苷酸膦酸酯类似物前药及其筛选和制备方法
AU2002250058B2 (en) * 2001-02-12 2007-08-16 Wyeth Llc Novel succinate salt of O-desmethyl-venlafaxine
AU2002341327A1 (en) * 2001-11-29 2003-06-10 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
GEP20063872B (en) * 2001-12-12 2006-07-10 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quina-zolin-6-yl}-allyl)-acetamide and method of production
US7214668B2 (en) * 2002-05-13 2007-05-08 Metabasis Therapeutics, Inc. Phosphonic acid based prodrugs of PMEA and its analogues
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
NZ575575A (en) * 2003-08-18 2010-04-30 Lundbeck & Co As H Succinate and malonate salt of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
HRP20060254A2 (en) * 2003-12-30 2006-10-31 Gilead Sciences Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
ATE445404T1 (de) 2004-01-21 2009-10-15 Gilead Sciences Inc Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
EP1965804A2 (de) * 2005-12-16 2008-09-10 Wyeth Pharmaceuticals Lipophile zusammensetzungen einer triazolpyrimidinverbindung
PL2020996T3 (pl) * 2006-05-16 2012-04-30 Gilead Sciences Inc Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego

Also Published As

Publication number Publication date
US20110172192A1 (en) 2011-07-14
ES2377467T3 (es) 2012-03-27
EA016995B1 (ru) 2012-09-28
JP2009537539A (ja) 2009-10-29
SI2020996T1 (sl) 2012-03-30
EA200802333A1 (ru) 2009-04-28
CN101442994B (zh) 2013-03-06
CA2652048C (en) 2012-12-11
CY1112377T1 (el) 2015-12-09
WO2007136650A3 (en) 2008-01-24
US8435969B2 (en) 2013-05-07
US20090258840A1 (en) 2009-10-15
AU2007254309B2 (en) 2012-05-03
CN101442994A (zh) 2009-05-27
WO2007136650A2 (en) 2007-11-29
US20080039427A1 (en) 2008-02-14
BRPI0711646B8 (pt) 2021-04-06
JP2013100324A (ja) 2013-05-23
BRPI0711646C1 (pt) 2021-05-25
EP2020996A2 (de) 2009-02-11
EP2020996B1 (de) 2011-11-23
KR20090015122A (ko) 2009-02-11
BRPI0711646A2 (pt) 2011-11-29
AU2007254309A1 (en) 2007-11-29
MX2008014665A (es) 2008-11-28
DK2020996T3 (da) 2012-02-27
HK1127913A1 (en) 2009-10-09
KR101424832B1 (ko) 2014-08-06
CA2652048A1 (en) 2007-11-29
PT2020996E (pt) 2012-02-20
NZ572368A (en) 2011-04-29
PL2020996T3 (pl) 2012-04-30
BRPI0711646B1 (pt) 2020-12-01
JP5544165B2 (ja) 2014-07-09

Similar Documents

Publication Publication Date Title
ATE534377T1 (de) Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
ECSP109953A (es) Derivados de piridazinona
EA201100447A1 (ru) Органические соединения
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
ATE536349T1 (de) In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
DE602004012079D1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA200802213A1 (ru) Способы лечения заболеваний крови
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA201000098A1 (ru) Производные хиназолинамида
TN2010000293A1 (en) Thiazole derivatives used as pi 3 kinase inhibitors
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
EA200802329A1 (ru) Производные триазола ii
ATE552000T1 (de) Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
UA99485C2 (ru) Хиназолиндионовые производные, их получение и их применение в терапии
DE602006010442D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
ATE441632T1 (de) Gesättigte und ungesättigte 3-pyridyl- benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
EA201200087A1 (ru) 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k
ATE464895T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen